EU antitrust regulators are investigating Israeli drugmaker Teva over the possible abuse of its dominant position related to its multiple sclerosis medicine Copaxone, reported Reuters.
The EU competition enforcer raided Teva in October last year and in January this year as part of its investigation.
Teva can face fines up to 10% of its global turnover if found guilty of breaching EU antitrust rules.
The US government sued Teva in August, accusing the drugmaker of causing the submission of false claims to Medicare by using kickbacks to boost sales of Copaxone, one of its lucrative drugs.
This is the company’s third run-in with EU antitrust regulators which have also charged the company with anti-competitive practices over its deal with rival Cephalon to delay selling a generic version of its sleep disorder drug modafinil.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
K&L Gates Expands Antitrust Practice with New Partners
May 15, 2024 by
CPI
Polish Regulators Probe PS Store and Steam for Antitrust Violations
May 15, 2024 by
CPI
French Regulator Meat-Cutting Sector Case Following Antitrust Review
May 15, 2024 by
CPI
Arizona Attorney General Files Suit Against Amazon Over Unfair Business Practices
May 15, 2024 by
CPI
Varsity Spirit and Private Equity Owners Settle Class Action Antitrust Suit
May 15, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI